Insider Transactions in Q4 2021 at Crispr Therapeutics Ag (CRSP)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 20
2021
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,750
+5.98%
|
$17,750
$1.81 P/Share
|
|
Dec 06
2021
|
James R. Kasinger General Counsel and Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
6,303
-12.65%
|
$434,907
$69.17 P/Share
|
|
Dec 06
2021
|
Tony W Ho Executive VP, Head of R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
12,607
-19.4%
|
$869,883
$69.17 P/Share
|
|
Dec 06
2021
|
Lawrence Otto Klein CBO & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,185
-33.38%
|
$771,765
$69.17 P/Share
|
|
Dec 06
2021
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37,818
-12.64%
|
$2,609,442
$69.17 P/Share
|
|
Dec 03
2021
|
James R. Kasinger General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
13,333
+21.1%
|
-
|
|
Dec 03
2021
|
Tony W Ho Executive VP, Head of R&D |
BUY
Exercise of conversion of derivative security
|
Direct |
26,667
+29.1%
|
-
|
|
Dec 03
2021
|
Lawrence Otto Klein CBO & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,667
+44.31%
|
-
|
|
Dec 03
2021
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
80,000
+21.1%
|
-
|
|
Dec 02
2021
|
James R. Kasinger General Counsel and Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,342
+16.74%
|
$95,446
$13.62 P/Share
|
|
Dec 01
2021
|
Samarth Kulkarni Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
779
-0.35%
|
$58,425
$75.1 P/Share
|
|
Oct 15
2021
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,000
+13.05%
|
$33,000
$1.81 P/Share
|